A clinical trial:To study the effect of Ayurvedic herbal drug in pelvic inflammatory diseases

Effect of Nirgundi Churna and Nirgundi Taila Yoni Pichu in Pelvic Inflammatory Disease (PID) - PID

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/04/013042

Enrollment

Registered

2018-04-04

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Married patients of active reproductive life (age 21-45 years) having symptoms and associated symptoms related with PID and also diagnosed to have PID for the preceeding 6-12 months

Interventions

Intervention1: Ayurvedic herbal drug formulation Nirgundi churna and Nirgundi taila : Nirgundi churna 3 gm BD orally with luke warm water for total 60 days at a regular intervel of 15 days, Nirgundi

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients who are willing to participate in present study after giving the proper consent. 2.Patient is married. 3.Patient having complain of lower abdominal pain, unusual vaginal discharges, pain during coitus, menstrual disorders, fever, associated symptoms related with PID and also diagnosed to have PID for the preceeding 6-12 months

Exclusion criteria

Exclusion criteria: 1.Patient is unmarried. 2.Patient is pregnant. 3.Patient suffering from any systemic disease like tuberculosis, diabetes mellitus, bronchial asthma, jaundice, cardiovascular disease, any renal problem. 4.Patient having any infection like TORCH, HIV, Hepatitis etc. 5.Patient having any drug allergy and psychological disorders. 6.Patient having any specific pathology of genital tract ie benign or malignant tumor, tubo-ovarian abscess, erosion of the cervix etc. 7.Patient suffering from any disease on external genital organs like any boil, infected cyst, bartholian gland abscess or any skin disease i.e. eczema, vulvo-vaginitis etc. 8.Patient with history of more than three episodes of PID. 9.Patient can not attend follow up regularly. 10.Patient not giving consent to participation in the study. 11.Patient who is participating in any research study.

Design outcomes

Primary

Measure	Time frame
Complains- lower abdominal pain, Pain during coitus with intensity of pain, unusual vaginal discharges, menstrual irregularities, fever sign- lower abdominal tenderness,cervical motion tenderness, fornices tenderness and adenexal tenderness and raised C-RP Investigation- USG of pelvic organ and adenexaTimepoint: Total five follow up will be done at a regular interval of 15 days. four follow up with medication and fifth follow up without medication.	—

Measure

Time frame

Complains- lower abdominal pain, Pain during coitus with intensity of pain, unusual vaginal discharges, menstrual irregularities, fever sign- lower abdominal tenderness,cervical motion tenderness, fornices tenderness and adenexal tenderness and raised C-RP Investigation- USG of pelvic organ and adenexaTimepoint: Total five follow up will be done at a regular interval of 15 days. four follow up with medication and fifth follow up without medication.

—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Sunita Suman

Banaras Hindu University

ssom18@gmail.com7607165096

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026